EBIT: Income before interest and taxes.
Kairos Pharma, Ltd. (KAPA) had EBIT of $-1.69M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.65M |
|
-- |
|
-- |
|
$1.69M |
|
$-1.69M |
|
$0.04M |
|
$-1.65M |
|
$-1.65M |
|
$-1.65M |
|
$-1.65M |
|
$-1.65M |
|
$-1.65M |
|
|
EBIT |
$-1.69M |
$-1.43M |
|
21.01M |
|
21.01M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$4.44M |
|
-- |
|
$1.30M |
|
$5.74M |
|
$0.43M |
|
-- |
|
-- |
|
$0.43M |
|
$5.31M |
|
$5.29M |
|
$5.31M |
|
21.41M |
|
| Cash Flow Statement Financials | |
$-1.04M |
|
-- |
|
$0.22M |
|
$4.49M |
|
$3.67M |
|
$-0.82M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.13% |
|
-31.26% |
|
-28.80% |
|
-31.13% |
|
$0.25 |
|
$-0.05 |
|
$-0.05 |
|